US3806594A - Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium - Google Patents

Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium Download PDF

Info

Publication number
US3806594A
US3806594A US00309397A US30939772A US3806594A US 3806594 A US3806594 A US 3806594A US 00309397 A US00309397 A US 00309397A US 30939772 A US30939772 A US 30939772A US 3806594 A US3806594 A US 3806594A
Authority
US
United States
Prior art keywords
cerebral palsy
involuntary movements
clorazepate dipotassium
movements associated
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00309397A
Inventor
Brien G O
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US00309397A priority Critical patent/US3806594A/en
Application granted granted Critical
Publication of US3806594A publication Critical patent/US3806594A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids

Definitions

  • Clorazepate dipotassium the dipotassium salt of 7- chloro-2,3dihydro-2-oxo-5-phenyll H-1 ,4- benzodiazepine-3-carboxylic acid, has previously been reported to be useful as an anticonvulsant agent, antidepressant, muscle relaxant, antianxiety agent and as a tranquilizer. (See, for example, U.S. Pat. No. 3,516,988).
  • a method of reducing the involuntary movement associated with cerebral palsy comprising orally administering to a cerebral palsy patient from 15 to 90 mg.

Abstract

A method of decreasing the involuntary movements associated with cerebral palsy using clorazepate dipotassium as the active agent.

Description

United States Patent [191 OBrien METHOD OF REDUCING INVOLUNTARY MOVEMENTS ASSOCIATED WITH CEREBRAL PALSY USING CLORAZEPATE DIPOTASSIUM [75] Inventor: George Sivesind OBrien, Lake Forest, Ill.
[73] Assignee: Abbott Laboratories, Chicago, Ill.
[58] Field of Search 424/244 1 Apr. 23, 1974 [56] References Cited UNITED STATES PATENTS 6/1970 Schmitt 424/244 Primary ExaminerStanley J. Friedman Attorney, Agent, or Firm-Robert L. Niblack; Joyce R. Krei [5 7] ABSTRACT A method of decreasing the involuntary movements associated with cerebral palsy using clorazepate dipotassium as the active agent.
1 Claim, No Drawings METHOD OF REDUCING INVOLUNTARY MOVEMENTS ASSOCIATED WITH CEREBRAL PALSY USING CLORAZEPATE DIPOTASSIUM Nil CH-C ozK-KOH The compound can be prepared according to Example 35 of US. Pat. No. 3,516,988.
Clorazepate dipotassium, the dipotassium salt of 7- chloro-2,3dihydro-2-oxo-5-phenyll H-1 ,4- benzodiazepine-3-carboxylic acid, has previously been reported to be useful as an anticonvulsant agent, antidepressant, muscle relaxant, antianxiety agent and as a tranquilizer. (See, for example, U.S. Pat. No. 3,516,988).
It has now been unexpectedly found that when clorazepate dipotassium is administered to cerebral palsy patients in oral doses of from 15 to 90 mg. per day, the involuntary movements associated with cerebral palsy are either greatly reduced or are completely stopped. The marked reduction or cessation of involuntary movements are sustained when the patient is maintained on clorazepate dipotassium.
I claim:
1. A method of reducing the involuntary movement associated with cerebral palsy comprising orally administering to a cerebral palsy patient from 15 to 90 mg.
daily of clorazepate dipotassium.
' a I 1 I F i
US00309397A 1972-11-24 1972-11-24 Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium Expired - Lifetime US3806594A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00309397A US3806594A (en) 1972-11-24 1972-11-24 Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00309397A US3806594A (en) 1972-11-24 1972-11-24 Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium

Publications (1)

Publication Number Publication Date
US3806594A true US3806594A (en) 1974-04-23

Family

ID=23198063

Family Applications (1)

Application Number Title Priority Date Filing Date
US00309397A Expired - Lifetime US3806594A (en) 1972-11-24 1972-11-24 Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium

Country Status (1)

Country Link
US (1) US3806594A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005227385B2 (en) * 1999-04-30 2008-12-11 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561988A (en) * 1967-06-08 1971-02-09 Domtar Ltd Method of treating lime

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561988A (en) * 1967-06-08 1971-02-09 Domtar Ltd Method of treating lime

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005227385B2 (en) * 1999-04-30 2008-12-11 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
AU2005227385C1 (en) * 1999-04-30 2009-05-21 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis

Similar Documents

Publication Publication Date Title
Freis et al. Treatment of essential hypertension with chlorothiazide (Diuril): its use alone and combined with other antihypertensive agents
McDermott Toxicity of streptomycin
ES2117642T3 (en) PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLES AND N-ETILEN GLYCOLS.
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
GB1518843A (en) Process for the preparation of hollow particulates
KR950007848A (en) Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
Zipser et al. Hypocalcemic tetany due to sodium phosphate ingestion in acute renal failure
MY124465A (en) Reduction of infarct volume using citicoline
ES8307496A1 (en) Galenic preparation.
Bennett et al. Competition for sulphate during detoxification in the gut wall
US4241086A (en) Method for treating rheumatism
US3806594A (en) Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium
Leonard Toxic effects of phenylbutazone
Daiber et al. Treatment of aplastic anemia with nandrolone decanoate
GB2171302A (en) Therapeutic hydroxyprolines
US3705946A (en) Method of treating hyperuricemia
Essig et al. The effect of pentobarbital on alcohol withdrawal in dogs
Quick et al. Vitamin K requirements of adult dogs and the influence of bile on its absorption from the intestine
JPH0610141B2 (en) AIDS viral disease treatment agent
PT891186E (en) Nasal administration of agents for treatment of delayed onset emesis
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
GB1210968A (en) Improvements in or relating to the treatment of gastric ailments
Acocella et al. Serum and urine concentrations of rifampicin administered by intravenous infusion in man
EP0372676A1 (en) Therapeutic preparation and method
US3764679A (en) Iodinin as an anti-hypertensive agent